NEWS

San Jose, CA — March 18, 2025 — >— Biomed Industries, Inc. (Biomed) announced today the expansion of its rare disease program with the development of NA-925 as a potential treatment for Friedreich Ataxia (FA), a rare and progressive neurodegenerative disorder.

Building on the successful completion of Phase 2/3 clinical trials of NA-921 for Rett Syndrome, Biomed developed NA-925 and is planning to initiate Phase 2 clinical trials of NA-925 later this year to evaluate its efficacy in treating Friedreich Ataxia.

Friedreich Ataxia is a rare genetic disorder that disrupts the central nervous system due to an inherited gene defect. Symptoms usually emerge in late childhood and progressively worsen, leading to difficulties in walking, fatigue, sensory changes, and impaired speech. The condition affects approximately 1 in 50,000 people in the United States and 1 in 40,000 people worldwide, making it the most common hereditary ataxia.

Biomed is also exploring the potential of NA-925 to treat related neurodegenerative disorders, including Spinocerebellar Ataxias (SCAs), Ataxia-Telangiectasia (AT), Dentatorubral-Pallidoluysian Atrophy (DRPLA), and Charcot-Marie-Tooth (CMT) Disease.

“Existing Friedreich Ataxia treatments often lead to significant side effects, such as elevated liver enzymes, headaches, nausea, stomach pain, diarrhea, and muscle pain,” said Dr. Lloyd Tran, CEO of Biomed Industries. “With its minimal and mild side-effect profile, NA-925 has the potential to be a promising and cost-effective alternative for patients who have limited therapeutic options.”

RARE DISEASES OF UNMET NEEDS

Friedreich Ataxia (“FA”) is caused by mutations in the FXN gene, is a genetic disorder that can be differentiated from other Ataxia and related conditions by its specific symptoms and genetic basis, including cardiomyopathy, scoliosis, and diabetes. Friedreich Ataxia is an inherited disorder that causes progressive damage to the nervous system. This can cause movement and sensory symptoms and trouble with walking and gait.

In FA, nerve fibers in the spinal cord and peripheral nerves break down, becoming thinner. In the brain, the cerebellum, part of the brain that coordinates balance and movement, is most affected. There is currently no effective disease modifying treatment for Friedreich Ataxia.

Other Genetic Ataxia as:

Spinocerebellar Ataxia as (SCAs): While both FA and SCAs cause Ataxia a, SCAs are characterized by different genetic mutations and varying clinical presentations, including different ages of onset and progression rates.

Ataxia-Telangiectasia (AT): is a clinically complex disorder characterized by Ataxia, telangiectasia (spider veins), and immunodeficiency, which differs from FA in the absence of scoliosis and cardiomyopathy.

Dentatorubral-Pallidoluysian Atrophy (DRPLA): is a form of Ataxia a with a different genetic basis and clinical presentation, including seizures and movement disorders.

Charcot-Marie-Tooth (CMT) Disease: is a group of disorders that affect the peripheral nerves, leading to muscle weakness and sensory loss, and can mimic some symptoms of FA, particularly in children.

ABOUT BIOMED INDUSTRIES:

Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer's disease, ALS, Major Depressive Disorder (MDD), Diabetes, Obesity, Metabolic dysfunction-associated Steatohepatitis (MASH), and rare diseases, including Rett Syndrome.

For further information, please visit Biomed Industries' official website: https://www.biomedind.com

CONTACT